These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37154471)

  • 1. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
    Ma L; Zhang L; Kobayashi M; Tao X; Qian Q; Cheng H; Liu S; Zhou Y; Chen Y; Zhang J
    J Dermatol; 2023 Jul; 50(7):847-855. PubMed ID: 37154471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
    Fujita K; Yagi M; Moriwaki S; Yoshida M; Graham D
    J Dermatol; 2021 Nov; 48(11):1640-1651. PubMed ID: 34435694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
    Ma L; Tao X; Liu S; Cheng H; Fang R; Zhao Y; Cha A; Encinas GA; Zhou Y; Deng Y; Zhang J
    Dermatol Ther (Heidelb); 2024 May; 14(5):1229-1243. PubMed ID: 38748345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
    Schlessinger J; Shepard JS; Gower R; Su JC; Lynde C; Cha A; Ports WC; Purohit V; Takiya L; Werth JL; Zang C; Vlahos B;
    Am J Clin Dermatol; 2020 Apr; 21(2):275-284. PubMed ID: 32212104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
    Luger TA; Hebert AA; Zaenglein AL; Silverberg JI; Tan H; Ports WC; Zielinski MA
    Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
    Spergel JM; Blaiss MS; Lio P; Kessel A; Cantrell WC; Takiya L; Werth JL; O'Connell MA; Zang C; Cork MJ
    Allergy Asthma Proc; 2021 Sep; 42(5):425-431. PubMed ID: 34474712
    [No Abstract]   [Full Text] [Related]  

  • 9. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
    Eichenfield LF; Yosipovitch G; Stein Gold LF; Kalabis M; Zang C; Vlahos B; Sanders P; Myers DE; Bushmakin AG; Cappelleri JC; Olivadoti M; Paller AS
    Pediatr Dermatol; 2020 Nov; 37(6):1030-1037. PubMed ID: 32981097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
    Silverberg JI; Tallman AM; Ports WC; Gerber RA; Tan H; Zielinski MA
    Acta Derm Venereol; 2020 Jun; 100(13):adv00170. PubMed ID: 32318744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
    Eichenfield LF; Stein Gold LF; Lynde C; Guenther L; Greenberger S; Chu CY; Ghodsi Z; Vlahos B; Sanders P; Cha A; Canosa JM
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):875-892. PubMed ID: 38546803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    Silverberg JI; Kirsner RS; Margolis DJ; Tharp M; Myers DE; Annis K; Graham D; Zang C; Vlahos BL; Sanders P
    J Am Acad Dermatol; 2024 May; 90(5):945-952. PubMed ID: 38340127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
    Callender VD; Alexis AF; Stein Gold LF; Lebwohl MG; Paller AS; Desai SR; Tan H; Ports WC; Zielinski MA; Tallman AM
    Am J Clin Dermatol; 2019 Oct; 20(5):711-723. PubMed ID: 31264114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
    Ahmed A; Solman L; Williams HC
    Br J Dermatol; 2018 Mar; 178(3):659-662. PubMed ID: 29205284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
    Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
    Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
    Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS
    J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
    Saeki H; Baba N; Oshiden K; Abe Y; Tsubouchi H
    J Dermatol; 2020 Jan; 47(1):17-24. PubMed ID: 31713267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
    Tom WL; Van Syoc M; Chanda S; Zane LT
    Pediatr Dermatol; 2016; 33(2):150-9. PubMed ID: 26777394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
    Zane LT; Kircik L; Call R; Tschen E; Draelos ZD; Chanda S; Van Syoc M; Hebert AA
    Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
    Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
    J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.